CLDN18 and neoplasm: In a Japanese study, moderate-to-strong CLDN18.2 expression [≥ 2 + membrane staining intensity in ≥ 40% of tumor cells (FAST eligibility criterion; see below)] was observed in 52% of primary tumors and 45% of lymph node metastases.